Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device


; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and healthcare reform, pharmaceutical pricing and reimbursement, access to the company’s products, international reference pricing, including most-favored-nation drug pricing, and other pricing related initiatives and policy efforts; the impact of tariffs and other trade restrictions or domestic sourcing requirements; expanded brand and class competition in the markets in which the company operates; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to the company; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties, including Sebela Pharmaceuticals; the impact of higher selling and promotional costs; efficacy, safety or other quality concerns with respect to the company’s marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing healthcare insurance coverage; the failure by the company or its third party collaborators and/or their suppliers to fulfill their or their regulatory or quality obligations; and volatility of commodity prices, fuel, and shipping rates that impact the costs and/or ability to supply the company’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings (including amendments thereto), available at the SEC’s Internet site (



Source link

  • Related Posts

    The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience

    The ESB Birthday Party Package includes a guided visit through the Observatory’s galleries and New York City’s best views on the 86th Floor deck, a private party room with a…

    After a year in Mexico, recovery has stalled for U.S. citizen girl with rare brain tumor, deported mother says

    Nearly a year ago, an 11-year-old U.S. citizen girl’s treatment for a rare brain tumor was interrupted when her parents were deported to Mexico. Her parents and her four siblings,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Water main break causes lane closures, slow traffic on Gardiner on Monday morning

    Water main break causes lane closures, slow traffic on Gardiner on Monday morning

    Nier Automata’s Yoko Taro is writing an Evangelion anime TV show

    Nier Automata’s Yoko Taro is writing an Evangelion anime TV show

    New details emerge about armed man shot and killed at Trump’s Mar-a-Lago | Donald Trump

    New details emerge about armed man shot and killed at Trump’s Mar-a-Lago | Donald Trump

    Teen surfers rescue family from cold water after their boat overturns

    Defense Secretary summons Anthropic’s Amodei over military use of Claude

    Defense Secretary summons Anthropic’s Amodei over military use of Claude

    Wise Law’s Top Ten Legal News Post for the Week of February 23, 2026